<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81815">
  <stage>Registered</stage>
  <submitdate>16/01/2007</submitdate>
  <approvaldate>22/01/2007</approvaldate>
  <actrnumber>ACTRN12607000068460</actrnumber>
  <trial_identification>
    <studytitle>A Multicentre Prospective Study to Investigate the Prevalence of Sexual Dysfunction and Quality of Life in Women with Breast Cancer receiving Aromatase Inhibitors</studytitle>
    <scientifictitle>A Multicentre Prospective Study to Investigate the Prevalence of Sexual Dysfunction and Quality of Life in Women with Breast Cancer receiving Aromatase Inhibitors</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Sexual Dysfunction</healthcondition>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The primary outcome is sexual functioning and of interest is the report of vaginal dryness, dyspareunia (painful sexual intercourse) and sexual satisfaction.  This will be measured with validated questionnaires at baseline (prior to treatment with aromatase inhibitors), at 3 months and at 6 months. The duration of observation is 6 months.
Participants will include women with a diagnosis of breast cancer who are menopausal at the time of recruitment (ie no menstruation for at least 6 months).These are women who will be receiving recommended treatment with aromatase inhibitors (not a trial intervention but routine treatment). Many breast tumours are "oestrogen sensitive," meaning the hormone oestrogen helps them to grow. Aromatase inhibitors can help slow or stop the growth of these tumours by lowering the amount of oestrogen in the body.</interventions>
    <comparator>No comparator.</comparator>
    <control />
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sexual activity questionnaire</outcome>
      <timepoint>At baseline and at 3 and 6 months after commencing on aromatase inhibitors.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Dyspareunia  visual analog scale</outcome>
      <timepoint>At baseline and at 3 and 6 months after commencing on aromatase inhibitors.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life (Functional Assessment of Cancer Therapy - Breast (FACT-B).</outcome>
      <timepoint>At baseline and at 3 and 6 months after commencing on aromatase inhibitors.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vaginal dryness (Functional Assessment of Cancer Therapy  endocrine symtpoms (FACT-ES)</outcome>
      <timepoint>At baseline and at 3 and 6 months after commencing on aromatase inhibitors.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Primary breast cancer. Post-menopausal (no menstrual periods for at least 6 months). 6-8 weeks post chemotherapy Not receiving adjuvant anti-oestrogen therapy at time of study entry Fluent in English Willingness to complete questionnaire.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Diagnosis of metastatic breast cancer.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Psychosocial</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/03/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Michael Friedlander</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Susan G Komen Foundation</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Whilst the long-term effects of chemotherapy and hormonal therapy with tamoxifen on sexual function and quality of life of women with breast cancer has been well documented, less is known about the impact of aromatase inhibitors (AIs) on a womans sexual functioning.  Common sexual issues raised have included vaginal dryness, painful sexual intercourse (dyspareunia) and a reduction in libido.   AIs have largely replaced tamoxifen as choice of hormonal treatment in post-menopausal women and as there will an increasing number of women on AIs, it is important to document the impact of AI use on sexual functioning.  The result of this study will raise the awareness of the potential effects of AI use and sexual dysfunction for both the physician and patient.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Sydney Central Coast Health Coast Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>South Eastern Sydney/Illawarra Area Health Service Human Research Ethics Committee - Northern Section</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Redcliffe-Caboolture Health Service District Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Central Northern Adelaide Health Services Ethics of Human Research Committee (TQEH &amp; LMH)</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eastern Health Research and Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peninsula Health Research &amp; Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Micahel Friedlander</name>
      <address>Psychosocial Research Group
Prince of Wales Hospital
Lvl 3 Dickinson Bldg
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93822586</phone>
      <fax />
      <email>Michael.friedlander@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kelly Mok</name>
      <address>Psychosocial Research Group
Prince of Wales Hospital
Lvl 3 Dickinson Bldg
Barker St
Randwick NSW 2031</address>
      <phone>+61 2 93823371</phone>
      <fax />
      <email>kelly.mok@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>